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After long debate about the worth of screening for lung
cancer, and even about the merits of doing a randomized
trial to address the issue, initial results from the ﬁrst
large-scale randomized controlled trial ever to show a
reduction in lung cancer mortality associated with screening
were announced to the public last November 4.
1 The story
behind this historical ﬁrst is informative, and the editor of
the Journal of Medical Screening played a role in that story.
But more of that later.
The National Lung Screening Trial (NLST), launched in
September 2002, is a U.S. National Cancer Institute (NCI)
sponsored study that is jointly conducted by Lung
Screening Study (LSS) screening centres, funded by NCI
Division of Cancer Prevention, and the American College
of Radiology Imaging Network (ACRIN), funded by the
NCI Division of Cancer Treatment and Diagnosis Cancer
Imaging Program. A detailed description of the trial over-
view, rationale and design has been published.
2 Brieﬂy,
53,454 eligible participants aged 55–74 were recruited by
33 screening centres and were randomly assigned after
giving written informed consent to receive either three
annual low-dose helical CT scans (LDCT; also called spiral
CT by many investigators) or posteroanterior view chest
X-rays. The term ‘low-dose’ is used because the average esti-
mated whole-body effective dose in the NLST is 1.5 mSv
versus 7 mSv for standard diagnostic chest CT. Because of
concerns about the radiation harms associated with CT
scans and other medical imaging tests
3–7, lower doses of
radiation are used in the screening setting despite higher res-
olution achievable with increased doses. (Because the esti-
mated average whole body effective dose of the single
posteroanterior chest X-ray is 0.02 mSv, the whole body
effective dose ratio of chest X-ray:LDCT:standard diagnostic
CT is about 1:75:350.)
Eligibility criteria for the trial included: a 30 pack year
history of cigarette smoking; smoking cessation 15 years
if a former smoker; no history of lung cancer; no history of
other life threatening cancers in the prior ﬁve years; no
hemoptysis or weight loss to suggest a diagnosis of lung
cancer; and no chest CT in the prior 18 months. The trial
had an estimated 90% power to detect a 20% relative
reduction in lung cancer mortality. Prior to the launch of
the NLST, a feasibility study conducted by six of the LSS
screening centres in 3318 former and current smokers estab-
lished the ability to recruit, randomize and retain volunteers
on a study of LDCT versus chest X-ray.
8,9
Four previous randomized trials of lung cancer screening
using chest X-ray with or without sputum cytology led to
widespread pessimism about the value of screening for
lung cancer.
10–18 None had shown a reduction in lung
cancer mortality, leading to the general perception that
any beneﬁts of routine lung cancer screening did not out-
weigh the harms. However, the trials had insufﬁcient
power to detect a reduction in lung cancer mortality. The
much larger randomized PLCO (Prostate, Lung, Colorectal
and Ovarian) screening trial, designed to have sufﬁcient stat-
istical power, compares chest X-ray with a usual care control
arm
19,20, but has also not shown a beneﬁt to date. The intro-
duction of helical CT represented an advance in technology
that triggered renewed enthusiasm for lung cancer screen-
ing.
21–27 Several single arm studies showed a high cancer
detection rate with LDCT relative to chest X-ray (as summar-
ized in reference 2).
2
There were subsequent calls for routine lung cancer
screening without waiting for further proof.
28 There were
projections that routine lung cancer screening would be
highly cost-effective in terms of life years saved,
28 but
counter-estimates that it would be cost-ineffective
29 or com-
pletely ineffective.
30 There were even suggestions that doing
randomized trials of lung cancer screening with LDCT in the
face of the positive single arm studies was unethical.
31,32
However, trying to prove with conﬁdence that a single arm
study demonstrates a reduction in lung cancer mortality is
like determining who won a baseball game based on the
score of one of the teams. And statistical modelling of
what the other team was likely to have scored provides
little additional conﬁdence. Powerful confounding factors
and systematic biases can muddy interpretation of uncon-
trolled screening studies.
33 The NCI accordingly proposed
the NLST as a deﬁnitive test of the hypothesis generated
by the single arm studies. Chest X-ray was chosen as the
control arm because it was already being compared with
usual care in the PLCO trial.
19,20,34
There are few issues in medicine that polarize the public,
their elected representatives and health professionals more
than medical screening. Polarization was evident during
preparation for proposing the NLST to the NCI National
Cancer Advisory Board. There were arguments, with little
evidence, that even conducting a screening trial would
leave the impression in the minds of smokers that they
need not stop smoking. There was concern that the cost of
a randomized trial would siphon money from more basic
investigator-initiated research projects. Finally, some were
already convinced that the well-known confounders (e.g.
healthy volunteer effect, lead time bias and length-biased
sampling) could not account for projections from some of
the single arm studies that LDCT would decrease lung
cancer mortality by at least 80%. And this is where the
editor of the Journal of Medical Screening enters the story.
Professor Wald was asked to review the merits of the trial
109
Journal of Medical Screening 2011 Volume 18 Number 3and to give an independent assessment to the National
Cancer Advisory Board. He made the case that a large ran-
domized trial of LDCT screening for lung cancer with lung
cancer mortality endpoints would be feasible, affordable
and should be instituted quickly. His endorsement of the
need for the trial played a crucial role in the decision to
fund the trial.
The NLST has been a success. Accrual was brisk, reaching
its target in April 2004. Compliance was high: 98.5%, 94.0%
and 92.9% in the three successive LDCT screens; 97.4%,
91.3% and 89.5% in the three chest X-ray screens. At its
sixth planned interim analysis in October 2010, the inde-
pendent Data and Safety Monitoring Board unanimously
recommended that the results be announced to the public
because the primary endpoint had been achieved: a statisti-
cally signiﬁcant 20.3% relative reduction in lung cancer
mortality in the LDCT arm. This represented an absolute
lung cancer mortality rate of 247 versus 309 per 100,000
person years with LDCT versus chest X-ray. By comparison,
the PLCO study, has shown no impact to date of chest X-ray
on lung cancer mortality either in the entire PLCO popu-
lation or in trial participants that met the eligibility criteria
for the NLST. Perhaps because lung cancer has such a
strong force of mortality in smokers and former smokers,
the reduction in lung cancer mortality was accompanied
by a statistically signiﬁcant 6.7% relative reduction in all-
cause mortality (1121 versus 1202 deaths per 100,000
person-years). The number of lung cancers diagnosed was
649 and 279 respectively. While it is too early to make an
accurate estimate, some of this excess may represent over-
diagnosis compared with chest X-ray – the detection of non-
lethal tumors that would not have surfaced had it not been
for screening. In addition, cumulative screen positivity rates
were 24.2% versus 6.9% in the LDCT and chest X-ray,
representing an added burden of follow-up associated with
LDCT. Although the consequences of the follow-up of
these tests have not yet been fully analyzed, the LSS feasi-
bility study showed that LDCT and chest X-ray triggered
invasive follow-up procedures in 7% and 4% of participants
who had a false positive test.
35
The NLST has provided a powerful answer to some of the
most contentious questions swirling around the issue of lung
cancer screening when Professor Wald assessed the state of
the evidence in 1999. It is clear that the efﬁcacy of LDCT
screening for lung cancer is not as large as the most optimis-
tic estimates from the single arm studies, nor as bad as the
statistical models predicting no beneﬁt. Such is the power
of a randomized controlled trial (RCT). The NLST has been
described as ‘the best umpire in town’ to help decide
whether CT screening represents a home run or foul
ball.
36 However, it has not answered all of the important
questions that are critical to public health policy decisions.
There are remaining issues to address, including the effect
on quality of life and adverse effects of treating overdiag-
nosed cancers. In this regard, the NLST has collected lung
pathology specimens that may allow a deeper understanding
of the molecular processes that underpin variations in bio-
logic behavior of the cancers. There are also planned and
ongoing formal studies of qualityof life and cost-effectiveness,
as well as modelling studies addressing optimal frequency of
screening and age range of optimal effectiveness. Questions
will still remain about whether the balance of beneﬁts and
harms found in a study conducted by centres that have
strong expertise in screening can be maintained in less regu-
lated and less quality-controlled settings in the general
community.
Undoubtedly, gaps in our knowledge will also be ﬁlled in
by other ongoing randomized clinical trials, such as the
Danish Randomized Lung Cancer CT Screening Trial
37, the
Detection and Screening of Early Lung Cancer (DANTE)
trial
38, the NELSON trial
39, the ITALUNG study
40, the LUSI
trial in Germany
41, and the U.K. Lung Screen (UKLS).
42
However the aggregate results turn out, we are well-served
by randomized controlled trials to provide high-level evi-
dence to inform decisions about whether to institute wide-
spread lung cancer screening as a matter of public health
policy. As pointed out by Dr. Robert Young, the chairperson
of the NLST Oversight Committee, randomized trials are the
best antidote available for medical controversy.
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